Mounjaro Price in 2026: What You Pay and How Insurance Changes It

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

“Mounjaro price” and “Mounjaro cost” get searched interchangeably, but the useful question is narrower: what will you actually pay once insurance is applied? This article separates the sticker price from the real price, explains how a plan reshapes the number, and outlines where compounded tirzepatide sits — all reported as published as of April 2026.

The sticker price versus the real price

Mounjaro’s list price is approximately $1,069 per month at U.S. list as of April 2026 (Eli Lilly published pricing). That sticker is rarely what an insured patient pays. It is the pre-negotiation figure that insurance, rebates, savings cards, and pharmacy pricing all act on before the number reaches the counter.

How your plan reshapes the number

Coverage depends on whether the prescription is written for an FDA-approved indication and on the plan’s formulary. Many commercial plans cover tirzepatide for type 2 diabetes; chronic weight-management coverage is more variable and frequently subject to prior authorization or BMI-based criteria. The same list price can produce wildly different out-of-pocket totals across two plans.

Savings programs and their limits

Eli Lilly publishes a manufacturer savings-card program that can substantially reduce monthly cost for eligible commercially-insured patients. Independent platforms such as GoodRx and SingleCare publish pharmacy coupon prices that vary by location. Eligibility and amounts change over time — the only reliable price is the one confirmed at the time of fill.

Compounded tirzepatide as a separate price track

Between 2022 and 2024 the FDA listed tirzepatide on its drug shortage list, opening a pathway for licensed 503A compounding pharmacies to compound tirzepatide formulations. The FDA resolved the shortage in 2024, narrowing but not eliminating that pathway. Legitimate compounded protocols prescribed through a state-licensed pharmacy run on their own pricing, independent of the brand’s list.

What makes the price move over time

The list figure is not fixed in the reader’s favor or against it. Manufacturer pricing, plan formulary decisions, prior-authorization criteria, savings-card terms, and the regulatory status of compounding all shift, and each can push the real price up or down between one fill and the next. That is why a number quoted in an article or forum can be stale by the time you reach the pharmacy — the durable habit is to re-confirm at the point of fill rather than anchor to a figure you read weeks earlier.

The PlexusDx protocols

PlexusDx offers clinician-supervised compounded GLP-1 protocols in its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, Tirzepatide Oral, Microdose GLP-1, and GLP-Squared — each with pricing published on its product page as of April 2026.

Upstream of any price comparison, the PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, and MC4R variants that shape baseline GLP-1, appetite-regulation, and energy-balance biology. That genetic context is the test before you invest framing behind every PlexusDx protocol.

Disclaimer: This article is educational. PlexusDx offers tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Learn more about the PlexusDx Tirzepatide protocol or the oral tirzepatide protocol inside the Weight Management Protocols collection, or take the Precision Peptide Genetic Test to start upstream.

Frequently Asked Questions

Why is Mounjaro’s price so high?

Mounjaro is a patent-protected branded medication, and Eli Lilly sets its roughly $1,069 monthly list price based on R&D cost recovery, market positioning, and expected payer mix. List prices have stayed high partly because demand outpaced manufacturing in 2023–2024. Savings programs and compounded options are the main levers patients use.

What will I actually pay with insurance?

It depends entirely on your plan. Coverage hinges on the FDA indication written, the formulary, and prior-authorization rules, so two insured patients can face very different out-of-pocket totals for the same list price. Confirm your plan’s terms and the indication on the prescription before assuming a number, since a quote that fits someone else’s coverage may not fit yours at all.

Is compounded tirzepatide priced differently?

Yes. Compounded tirzepatide from licensed 503A pharmacies runs on its own pricing, separate from Mounjaro’s list price, and has historically been lower. Compounded products are legally and factually different from the FDA-approved brand and are not generics. Discuss suitability with a qualified clinician.

Does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

It does not predict response to Mounjaro or set its price. It analyzes pathway-level variants in FTO, and MC4R that shape baseline GLP-1 and energy-balance biology — the upstream context that applies across every GLP-1 compound regardless of what any product costs.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education